Scancell Hldgs Plc (LON:SCLP)
23.90p-2.45%
Spriggl Score: Weak— see the number + sub-scores with a free Spriggl account
Last 30 trading days
Spriggl AI Verdict
“Promising cancer vaccine; Phase 3-ready with strong trial data, but deal or raise needed before year-end.”
Sign up free to read the full investment thesis, bull case, bear case and what to watch.
About Scancell Hldgs Plc
Scancell Holdings plc, a clinical stage biopharmaceutical company, discovers and develops of immunotherapies for the treatment of cancer in the United Kingdom. Its product candidates include SCIB1/iSCIB1+ that is in Phase II for the treatment of melanoma; and SC134, an antibody f…
- Sector:
- Healthcare
- Industry:
- Biotechnology
- Market Cap:
- £236.1M
Recent dividends
No recent dividends recorded.
Get the full Spriggl analysis — free
Sign up for a free Spriggl account to unlock the full Spriggl Score breakdown, screener, watchlist, and AI investment analysis on Scancell Hldgs Plc and 1,600+ UK and US stocks.
Start free